Abstracts tagged "Biologic agents"

Abstract Number: 470 • 2014 ACR/ARHP Annual Meeting
Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate-Related Lymphoproliferative Disorder
Shuntaro Saito¹, Yuko Kaneko¹, Katsuya Suzuki¹, Michihide Tokuhira² and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Hematology., Saitama Medical Center, Saitama Medical University., Saitama, Japan
Background/Purpose Lymphoproliferative disorder (LPD) is a rare complication in patients with rheumatoid arthritis(RA) treated with methotrexate(MTX). Although not a few patients experience exacerbation of RA…
Abstract Number: 2371 • 2014 ACR/ARHP Annual Meeting
Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra
Herman F. Mann^1,2, Sarka Forejtova³, Katerina Jarosova⁴, Ladislav Senolt⁵, Jakub Zavada⁶, Michal Uher⁷, Karel Hejduk⁷ and Karel Pavelka⁸, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁴Na Slupi 4, Institute of Rheumatology, Prague, Czech Republic, ⁵Na Slupi 4, Revmatologicky ustav, Prague, Czech Republic, ⁶Charles University, Prague, Czech Republic, ⁷Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: The biological disease-modifying anti-rheumatic drugs (bDMARDs) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic DMARDs (csDMARDs). However…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 280 • 2014 ACR/ARHP Annual Meeting
Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry
Katerina Jarosova¹, Karel Hejduk², Michal Uher² and Jiri Vencovsky, MD, DSc³, ¹clinical, Institution of Rheumatology, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic
Background/Purpose To analyze the efficacy and safety of biologic agents in adult patients with juvenile idiopathic arthritis (JIA).Methods ATTRA is the Czech national registry of…
Abstract Number: 2372 • 2014 ACR/ARHP Annual Meeting
Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting
H Corominas¹, C Alegre de Miguel², M Rodríguez-Gómez³, C Marras Fernández-Cid⁴, F Maceiras Pan⁵ and ACT-AXIS Study Group, ¹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ²Rheumatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology, Complejo Hospitalario Cristal Piñor, Ourense, Spain, ⁴Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁵Rheumatology, Complejo Hospitalario Arquitecto Marcide-Profesor Novoa Santos, A Coruña, Spain
Background/Purpose: Fatigue in RA possibly resulting from alterations in the HPA axis like occurs with others RA symptoms as morning stiffness, and mood and sleep…
Abstract Number: 1357 • 2014 ACR/ARHP Annual Meeting
Improving Compliance for Tuberculosis Screening for Patients on Biologics in Rheumatology Clinics
Shraddha Jatwani¹, Rajani Rudrangi¹, Karan Jatwani², Vijaya Murthy¹, Rashmi Maganti¹, Rex McCallum¹ and Emilio Gonzalez¹, ¹Rheumatology, University of Texas Medical Branch, Galveston, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Biologics are used commonly for patient with autoimmune diseases. These agents have ensured important efficacy advantages in the treatment of inflammatory rheumatic diseases. All…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 2388 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)
Thao Pham¹, Jacques Morel², Toni Alfaiate³, Emmanuelle Dernis⁴, Philippe Gaudin⁵, Olivier Brocq⁶, Elisabeth Solau-Gervais⁷, Jean-Marie Berthelot⁸, Jean-Charles Balblanc⁹, Xavier Mariette¹⁰, Florence Tubach¹¹ and Bruno Fautrel¹², ¹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁴Le Mans Hospital, Le Mans, France, ⁵Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁶Hospital of Princesse Grâce de Monaco, Monaco, France, ⁷Rheumatology, University Hospital of Poitiers, Poitiers, France, ⁸Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁹Rheumatology, Centre Hospitalier Général de Belfort, Belfort, France, ¹⁰Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ¹¹INSERM, Universite Paris Diderot, Paris, France, ¹²Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The STRASS trial was a 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…
Abstract Number: 1737 • 2013 ACR/ARHP Annual Meeting
Association Of HLA-DRB1 Alleles With Clinical Responses To The Anti-Interleukin−17A Monoclonal Antibody Secukinumab In a Cohort Of Patients With Active Rheumatoid Arthritis: An Exploratory Phase 2 Biomarker Study
Gerd Burmester¹, Patrick Durez², Galina Shestakova³, Yue Li⁴, Amanda Wang⁵, Steve Lewitzky⁵, Irina Koroleva⁵, David Lee⁶ and Wolfgang Hueber⁷, ¹Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Université Catholique de Louvain, Brussels, Belgium, ³Kaluga State Pedagogical Tsiolkovsky University, Kaluga, Russia, ⁴IIS, Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharma AG, Cambridge, MA, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Translational Medicine Autoimmunity, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The shared epitope (SE) may play a functional role in RA via Th17/interleukin (IL)-17 polarization (Holoshitz et al. FEBS Lett 2011;585:3619-26). Two phase 2…
Abstract Number: 1038 • 2013 ACR/ARHP Annual Meeting
Impact Of Biological Treatment On Overall Mortality and On Incidence Of Second Cancers In Arthritis Patients – A Follow-Up Study From The Danish Danbio Registry
Lene Dreyer¹, Lene Mellemkjær², Inger Marie Jensen Hansen³ and Merete Lund Hetland⁴, ¹Internal Medicine - Rheumatology Section, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark, ²Danish Cancer Society Research Center, Copenhagen, Denmark, ³Department of Reumatology, OUH Svendborg Hospital, Svendborg, Denmark, ⁴Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: It is largely unknown whether it is safe to treat arthritis patients with a previous malignancy with biologics. Only a few studies have address…
Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Sarah Ringold¹, Pamela F. Weiss², Robert A. Colbert³, Esi Morgan DeWitt⁴, Tzielan C. Lee⁵, Karen Onel⁶, Sampath Prahalad⁷, Rayfel Schneider⁸, Susan Shenoi⁹, Richard K. Vehe¹⁰ and Yukiko Kimura¹¹, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³NIAMS NIH, Bethesda, MD, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁷Pediatrics, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁹Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, ¹⁰Department of Pediatrics, University of Minnesota, Minneapolis, MN, ¹¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…
Abstract Number: 2367 • 2013 ACR/ARHP Annual Meeting
Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
Luis Rodriguez-Rodriguez¹, Leticia Leon², Zulema Rosales², Cristina Lajas², Lucía Arietti², Ana B. Rodríguez-Cambrón², Cristina Martínez-Prada², Jose María Leal², Pilar Macarrón², Gloria Candelas², Juan A. Jover² and Lydia Abásolo², ¹Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To describe in a cohort of rheumatoid arthritis (RA) patients followed up to 12 years, in standard clinical practice, the rate of biological agents…
Abstract Number: 1555 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Drug Survival In Psoriatic Arthritis Patients Treated In Ordinary Clinical Practice
Glenn Haugeberg¹, Andreas P. Diamantopoulos¹, Agnete Gulati², Mari Hoff³ and Arthur Kavanaugh⁴, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, St.Olavs Hospital, Trondheim, Norway, ³Rheumatology, St Olavs Hospital, Trondheim, Norway, ⁴University of California San Diego, San Diego, CA
Background/Purpose: The use of TNF-inhibitors in psoriatic arthritis (PsA) has been shown to improve clinical and radiographic outcome in randomized controlled trials (RCT) and shown…
Abstract Number: 1051 • 2013 ACR/ARHP Annual Meeting
Sociodemographic, Health System, and Community Characteristics Associated With Initiation Of Biological Dmards In RA
Edward H. Yelin¹, Chris Tonner², Seoyoung C. Kim³, Jeffrey N. Katz⁴, John Z. Ayanian⁵ and Daniel H. Solomon⁶, ¹Medicine, UC San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: The use of biologic DMARDs for RA has improved outcomes, but it is unknown whether there are disparities in initiation of these agents by…
Abstract Number: 2370 • 2013 ACR/ARHP Annual Meeting
The Effectiveness Of Biological Agents Concomitant With Tacrolimus In Rheumatoid Arthritis
Kenya Terabe¹, Toshihisa Kojima², Nobunori Takahashi¹, Koji Funahashi³, Atsushi Kaneko⁴, Daihei Kida⁵, Yuichiro Yabe⁶, Yuji Hirano⁷, Masatoshi Hayashi⁸ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁵Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁶Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, ⁷Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁸Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan
Background/Purpose:In Japan, oral tacrolimus (TAC) was approved for the treatment of RA in 2005 and the improvement of symptoms thorough the use concomitant with disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].